These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 18986464)

  • 21. Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
    Hepper DM; Wu P; Anadkat MJ
    J Am Acad Dermatol; 2011 May; 64(5):996-8. PubMed ID: 21496710
    [No Abstract]   [Full Text] [Related]  

  • 22. Common side effects of anti-EGFR therapy: acneform rash.
    Sipples R
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption.
    Takata T; Tarutani M; Zouboulis CC; Sano S
    J Dermatol Sci; 2012 May; 66(2):165-8. PubMed ID: 22440861
    [No Abstract]   [Full Text] [Related]  

  • 24. EGFR-targeted therapy and related skin toxicity.
    Morse L; Calarese P
    Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis.
    Cuétara MS; Aguilar A; Martin L; Aspiroz C; del Palacio A
    Br J Dermatol; 2006 Aug; 155(2):477-9. PubMed ID: 16882195
    [No Abstract]   [Full Text] [Related]  

  • 26. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
    Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B
    Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903
    [No Abstract]   [Full Text] [Related]  

  • 27. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 28. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
    Oskan F; Belka C; Manapov F
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919
    [No Abstract]   [Full Text] [Related]  

  • 30. Grading of severe follicular rash in patients receiving EGFR inhibitors.
    Manganoni AM; Farisoglio C; Ferrari V; Zaniboni A; Beretta G; Meriggi F; Calzavara-Pinton P
    Ann Surg Oncol; 2010 Jan; 17(1):349. PubMed ID: 19821000
    [No Abstract]   [Full Text] [Related]  

  • 31. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe purpuric xerotic dermatitis associated with gefitinib therapy.
    Sheen YS; Hsiao CH; Chu CY
    Arch Dermatol; 2008 Feb; 144(2):269-70. PubMed ID: 18283195
    [No Abstract]   [Full Text] [Related]  

  • 33. Cetuximab-induced acneiform eruption and the response to isotretinoin.
    Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
    Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
    [No Abstract]   [Full Text] [Related]  

  • 34. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
    Gerber PA; Kukova G; Buhren BA; Homey B
    Dermatology; 2011; 222(2):144-7. PubMed ID: 21346311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.
    Lacouture ME; Lai SE
    Br J Dermatol; 2006 Oct; 155(4):852-4. PubMed ID: 16965448
    [No Abstract]   [Full Text] [Related]  

  • 36. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
    Campbell TM; Brown CW
    J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A man whose scapula was spared a drug-associated rash.
    Sanz A; del Valle ML
    CMAJ; 2005 Mar; 172(6):745. PubMed ID: 15767607
    [No Abstract]   [Full Text] [Related]  

  • 38. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
    Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
    Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
    Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
    Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
    Blume JE; Miller CC
    Int J Dermatol; 2007 Dec; 46(12):1307-8. PubMed ID: 18173531
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.